Robert Mendes, MD
Vascular Surgery · Raleigh, NCNPI 1407941784
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $259,732 of the $408,069 with a category attached, or 63.6%. 31 manufacturers reported payments, led by Philips North America LLC at 35.1% of the total. Reporting peaked in 2019 at $119,641 and has fallen 74.2% since, to $30,887 in 2025. Among vascular surgery clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $645.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$143K
- Boston Scientific$80K
- Medtronic$77K
- Contego Medical, Inc$34K
- Asahi Intecc USA, Inc.$18K
- Penumbra, Inc.$17K
- plus $38K from 25 others
Across 131 payments — averaging $6644.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Research Incorporated$638K
- Penumbra, Inc.$99K
- W. L. Gore & Associates, Inc.$52K
- Boston Scientific$45K
- Bard Peripheral Vascular, Inc.$18K
- Merit Medical Systems Inc$15K
- plus $4K from 2 others
What the payments were for
- Consulting fees$40,07910%
- Speaking & faculty fees$259,73264%
- Travel & lodging$73,93118%
- Food & beverage$18,1264%
- Education$4,0001%
- Gifts$1,2000%
- Other$11,0003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 135 | $143,354 |
| Boston Scientific | 155 | $80,410 |
| Medtronic(2 entities) | 201 | $76,602 |
| Contego Medical, Inc | 17 | $34,026 |
| Asahi Intecc USA, Inc. | 14 | $18,196 |
| Penumbra, Inc. | 26 | $17,271 |
| Cook Incorporated | 8 | $14,886 |
| Angiodynamics, Inc. | 3 | $11,018 |
| Cook Medical LLC | 3 | $5,981 |
| Surmodics, Inc. | 1 | $1,667 |
| Endologix LLC | 6 | $975 |
| KCI USA, Inc. | 1 | $850 |
| Cordis US CORP. | 1 | $825 |
| W. L. Gore & Associates, Inc. | 23 | $372 |
| Abbott | 12 | $276 |
| Shockwave Medical, Inc | 3 | $240 |
| Silk Road Medical, Inc. | 1 | $191 |
| Bolton Medical Inc | 2 | $163 |
| Bard Peripheral Vascular, Inc. | 2 | $139 |
| Canon Medical Systems USA, Inc. | 4 | $139 |
| Rapid Medical Ltd | 1 | $124 |
| Edwards Lifesciences | 2 | $84 |
| Terumo Medical Corporation | 1 | $59 |
| Walk Vascular, LLC | 1 | $44 |
| Sirtex Medical Inc | 2 | $40 |
| Amgen | 2 | $35 |
| EKOS Corporation | 1 | $28 |
| Smith+Nephew | 1 | $27 |
| Johnson & Johnson | 1 | $27 |
| Flowphysix Inc | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- US Und$40,187
- IGT D Peripheral$36,505
- Abre$33,913
- Spectranetics Undiv$30,959
- (9520) IGT Devices Undivided$22,815
- Indigo System$15,613
- JETSTREAM$14,500
- PERIPHERAL VASCULAR$14,021
- Auryon Laser System 100-120 Vac$11,000
- Cook Medical Stents$10,731
- GENERAL - STENTS$10,500
- GENERAL VASCULAR INTERVENTION$9,203
- AngioJet Ultra 5000A$8,600
- ANGIOJET$7,058
- Cook Medical AAA$5,963
- HawkOne$5,850
- GENERAL - THERAPIES$5,531
- IN.PACT Admiral$5,486
- GENERAL THROMBECTOMY$5,000
- IVUS Systems$4,800
How this compares
$408,069 in reported general payments places this provider in the 95th percentile of 119 vascular surgery providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $57,910 |
| XareltoRivaroxaban | 21 | $17,161 |
| Repatha SureclickEvolocumab | 17 | $9,425 |
| ClopidogrelClopidogrel Bisulfate | 140 | $931 |
| Cilostazol | 11 | $216 |
| Prednisone | 11 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $27 | $17,16121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 119 vascular surgery providers in North Carolina.
Other vascular surgery in Raleigh
- Ellen DillavouRaleigh$284K
- Christopher McQuinnRaleigh$77K
- Joseph SalfityRaleigh$13K
- Jason KimRaleigh$8K
- Kirk CharlesRaleigh$8K
- Liliana NanezRaleigh$7K
- Heather WaldropRaleigh$5K
- Jacek PaszkowiakRaleigh$4K
- James FogartieRaleigh$3K
- Frank ArkoCharlotte$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.